All Pfizer published press releases by date and/or category of news
12.05.2022 Vaccines COVID-19 Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years 12.01.2022 Financial Finance Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day 12.01.2022 Vaccines Research Vaccines Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate 11.28.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 11.18.2022 Vaccines COVID-19 Vaccines Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages 11.11.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 11.10.2022 Vaccines COVID-19 Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union 11.04.2022 COVID-19 Vaccines Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine 11.03.2022 Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma 11.01.2022 Financial Finance PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK 11.01.2022 Vaccines Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate 10.18.2022 Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022
The latest news from Pfizer and its strategic partners
12.01.2022 Corporate Partnerships Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases 11.10.2022 Corporate Partnerships Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.